Navigating the Complexities of Rare Disease Research: Challenges and Digital Solutions
Rare diseases demand rapid scientific progress, yet the field remains severely under-resourced. More than 7,000 rare diseases have been identified, affecting an estimated 20–30 million people in the U.S. alone. Because most are monogenic, many are strong candidates for gene therapy and enzyme replacement therapy, as illustrated by the recent success of a personalized CRISPR-based treatment for Baby KJ, who suffered from severe carbamoyl-phosphate synthetase I deficiency.
By 2025, gene therapies and enzyme replacement therapies accounted for 22% and 15% of the roughly 800 therapies in development, respectively. Small molecules still represent the largest share at 33%. As this therapeutic pipeline grows and becomes increasingly competitive, researchers face mounting pressure to manage, integrate, and interpret complex, multimodal datasets, manage multi-partner collaborations with academic and contract research institutions, and, ultimately, translate the next generation of therapies into the clinic.
This rapid pace highlights the limitations of traditional R&D environments: Siloed data storage, spreadsheet-driven tracking, and disconnected software and instrumentation. Integrated digital platforms help overcome these barriers, providing the unified infrastructure needed to accelerate discovery with accuracy and confidence.
In the blog below, we explore the key challenges in rare disease research, the evolution of digital solutions, and how Signals One™ and Signals Synergy™ from Revvity Signals can transform modern R&D workflows.
The Challenges in Rare Disease Research
Rare disease research must overcome substantial scientific and operational hurdles to advance therapies into the clinic. In part, these translational burdens have persisted due to reliance on traditional, antiquated tools that don’t support the workflows and operations of modern-day R&D labs.
Data scarcity and fragmentation
Because rare diseases affect fewer than 200,000 individuals in the U.S., patient populations are inherently small. This leads to a limited understanding of disease mechanisms and natural history. At the same time, the data that is generated – clinical histories, genomic profiles, imaging results, assay outputs, and biomarker measurements – is often dispersed across instruments, platforms, and organizations, creating significant fragmentation.
Dispersed collaboration
For rare disease research, every patient provides meaningful biological insights. And because rare disease patient populations are small and dispersed, research teams need to form multi-site collaborations across hospitals, academia, and patient foundations.
Without clearly defined, structured collaborations or digital tools to manage version control, parallel workflows, and communication, collaborations and partnerships can be slow and error-prone, hindering progress.
Regulatory compliance
Genomic, pediatric, and longitudinal preclinical and clinical data all require strict access controls, traceability, and validated processes. Because research often spans multiple countries, teams must also navigate different regulatory frameworks, adding another layer of operational complexity.
Resource constraints
Small patient cohorts and limited funding magnify the impact of inefficiency. Delays in data processing, communication, or decision-making can slow discovery and extend timelines. Driving efficiency through digital integration is essential to maximizing the impact of every study and every dollar invested.
Finding Digital Solutions in an Evolving Landscape
Rare disease teams have long relied on manual, disconnected systems to manage data, protocols, and operations. Paper notebooks, isolated databases, and scattered spreadsheets were never designed for today’s research demands, especially in environments generating high-density datasets and outputs from high-throughput screening platforms.
As genetic and phenotypic data volumes grow, driven by next-generation gene, biologic, and small-molecule therapies, integrated digital solutions have emerged.
Modern R&D platforms provide:
- Unified data management
- Real-time collaboration across organizations
- Built-in compliance and traceability
- Configurable workflows tailored to rare disease research
Together, these capabilities create a central hub for managing data, samples, inventory, and protocols. By reducing fragmentation and establishing a single source of truth, integrated platforms accelerate insight generation and help advance discoveries toward the clinic, addressing the translational bottlenecks that have challenged rare disease pipelines for decades.
Accelerating Rare Disease Research Workflows with Revvity Signals
Rare disease R&D requires a digital infrastructure that connects evidence, context, and decisions across uncertain timelines.
Revvity Signals makes this vision a reality with a complementary ecosystem – Signals One and Signals Synergy – designed to help teams integrate knowledge and makes confident decisions in the face of limited and/or heterogeneous data.
Signals One: A decision-layer hub for rare disease programs
Signals One serves as a central decision layer for rare disease research, connecting experimental results, clinical observations, biomarker findings, and external analyses into a structured, traceable environment.
Rather than replace specialized genomics, proteomics, or imaging pipelines, Signal One connects the outputs with experimental context and program history. This is essential for rare diseases, where heterogeneous phenotypes and genetic variants (such as the hundreds of mutation patterns seen in disorders like Niemann-Pick disease type C), sparse datasets, and evolving hypotheses require interpretation over time, not analysis in isolation.
By organizing evidence across modalities, including small molecules, biologics, and gene-based approaches, and studies, Signals One helps teams:
- Track how conclusions were reached as data accumulates
- Compare competing hypotheses and therapeutic strategies
- Maintain continuity as programs evolve, teams change, or priorities shift
These capabilities establish a shared, transparent record of scientific rationale that supports more consistent and defensible decision-making.
Signals Synergy: Reducing friction across partners and programs
Signals Synergy supports streamlined collaboration among pharma and biotech institutions and research partners, including CROs. It helps preserve context, traceability, and alignment across organizational boundaries.
Through a shared workspace, controlled access, and structured review workflows, Signals Synergy helps teams:
- Maintain a single source of truth for program decisions
- Track changes, reviews, and approvals over time
- Preserve scientific intent as data moves between partners
In other words, Signals Synergy acts as a clear and auditable record of what was done, why, and how it informed decision making throughout the lifecycle of a collaboration.
Signals One + Signals Synergy
Enabling confident decisions across modalities
Signals One and Signals Synergy work together to provide secure, auditable environments that support regulatory compliance, data governance, and controlled access. These are critical capabilities for rare disease programs working with vulnerable populations and longitudinal datasets.
As rare disease pipelines increasingly span small molecules, biologics, and gene-based approaches, teams need systems that connect evidence across modalities without forcing all data into a single analytical paradigm. Signals One and Signals Synergy support this reality by enabling teams to manage knowledge, decisions, and collaboration from early discovery through translational and clinical stages.
Building the Future of Rare Disease Research with Revvity Signals
Rare disease programs face substantial challenges, including data fragmentation, limited patient cohorts, and regulatory complexity.
Integrated digital transformation provides a clear path forward for rare disease R&D teams, enabling high-quality collaborations and decision-making.
Signals One and Signals Synergy provide a solid foundation connecting heterogeneous evidence into a coherent, traceable research narrative. This foundation supports advanced analytics and modeling where appropriate, while ensuring that conclusions remain transparent, reviewable, and grounded in context.
By embracing digital innovation, researchers can shorten the path from discovery to patient impact, delivering new hope to the millions living with rare diseases.
Ready to explore how Revvity Signals can strengthen and scale your rare disease research?
Request a demo today!
Zev Wisotsky, Ph.D.
Director of Drug DiscoveryZev Wisotsky, PhD, is Director of Drug Discovery – Biologics Lead at Revvity Signals. A former bench neuroscientist, his background spans molecular biology, biochemistry, and drug discovery. For the past decade he has worked with biotech and pharma teams to simplify complex scientific workflows and bring connected software platforms into modern R&D.